ARTICLE | Company News
Cellectar and Pierre Fabre extend PDC deal
October 13, 2017 7:47 PM UTC
Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads with Cellectar's phospholipid ether drug conjugates (see BioCentury, Jan. 4, 2016)...